MINTEZOL
LOE ApproachingNDAORALTABLET, CHEWABLEPriority Review
Approved
Apr 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MINTEZOL (thiabendazole) is an oral anthelmintic medication approved in 1967 for treating parasitic worm infections. The drug is formulated as chewable tablets for systemic administration. It represents a legacy small-molecule therapeutic in a mature indication area.
LOE Approaching
Late-stage product with moderate competitive pressure (30%), indicating defensive market positioning and likely right-sizing of commercial infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Positions on MINTEZOL align with mature-product management in specialized therapeutic areas, emphasizing market defense and cost optimization over launch execution. Career growth potential is limited, making this role most suitable for professionals seeking expertise in niche parasitology markets or transition planning.
Brand ManagerField Sales Representative
Worked on MINTEZOL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.